March 23, 2024

The FDA has agreed to delete years-old so­cial me­dia posts dis­cour­ag­ing the use of iver­mectin to treat Covid-19 as part of a set­tle­ment agree­ment in

Law­mak­ers on the Sen­ate HELP com­mit­tee are putting pres­sure on HHS to amp up its re­sponse to the re­cent cy­ber­at­tack on Change Health­care, the fall­out

Fol­low­ing Lenz Ther­a­peu­tics’ de­but on the Nas­daq Fri­day, End­points News spoke with CEO Eef Schim­melpen­nink about the think­ing be­hind choos­ing a re­verse merg­er over an

The EU re­view of Ei­sai’s Alzheimer’s drug lecanemab was de­layed this week be­cause of a pro­ce­dur­al is­sue at the Eu­ro­pean Med­i­cines Agency. On Fri­day, Ei­sai

Long­time on­col­o­gy com­mer­cial leader Chip Romp is mak­ing a cre­ative leap and join­ing the board of di­rec­tors at de­sign-fo­cused health­care agency minds + as­sem­bly. Romp

Plus, news about OKYO Phar­ma: In­tel­lia de­parts Re­gen­eron deal: The CRISPR biotech dis­closed Fri­day that it had opt­ed out of a part­ner­ship with Re­gen­eron to

Nkar­ta hit the brakes on one of its lead pro­grams Thurs­day af­ter­noon, de­pri­or­i­tiz­ing a CAR-NK ther­a­py de­signed to treat an ag­gres­sive form of leukemia af­ter

Many of the em­ploy­ees be­hind GSK’s late-stage in­ves­ti­ga­tion­al drug for chron­ic cough will be let go at the end of March. “Af­ter hav­ing com­plet­ed the

No­vo Nordisk is an­oth­er step clos­er to launch­ing its once-week­ly in­sulin icodec now that the Eu­ro­pean Med­i­cines Agency’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use